Amedisys Inc (NASDAQ:AMED) saw some unusual options trading activity on Monday. Investors bought 2,242 put options on the stock. This represents an increase of approximately 1,679% compared to the typical volume of 126 put options.
Several brokerages have recently commented on AMED. Benchmark upgraded shares of Amedisys from a “hold” rating to a “buy” rating and set a $125.00 target price for the company in a report on Tuesday. Craig Hallum downgraded shares of Amedisys from a “buy” rating to a “hold” rating and lowered their target price for the company from $116.00 to $104.00 in a report on Friday, October 26th. Bank of America set a $139.00 target price on shares of Amedisys and gave the company a “buy” rating in a report on Tuesday, September 18th. Canaccord Genuity began coverage on shares of Amedisys in a report on Thursday, September 13th. They issued a “neutral” rating and a $117.00 target price for the company. Finally, ValuEngine upgraded shares of Amedisys from a “buy” rating to a “strong-buy” rating in a report on Monday, July 30th. Five equities research analysts have rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $102.38.
In other news, insider David B. Pearce sold 398 shares of the stock in a transaction dated Tuesday, September 25th. The shares were sold at an average price of $121.71, for a total value of $48,440.58. Following the completion of the sale, the insider now owns 11,818 shares in the company, valued at $1,438,368.78. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 2.60% of the company’s stock.
AMED opened at $115.18 on Wednesday. The stock has a market cap of $3.13 billion, a P/E ratio of 52.04, a P/E/G ratio of 1.50 and a beta of 1.00. The company has a debt-to-equity ratio of 0.30, a current ratio of 1.21 and a quick ratio of 1.21. Amedisys has a fifty-two week low of $45.60 and a fifty-two week high of $127.38.
Amedisys (NASDAQ:AMED) last posted its quarterly earnings results on Monday, October 29th. The health services provider reported $0.95 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.77 by $0.18. The company had revenue of $417.34 million during the quarter, compared to analyst estimates of $411.05 million. Amedisys had a net margin of 4.46% and a return on equity of 20.11%. The firm’s revenue for the quarter was up 11.7% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.56 earnings per share. Analysts predict that Amedisys will post 3.39 earnings per share for the current year.
Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, and aides for its patients to complete their important personal tasks.
Recommended Story: Diversification For Individual Investors
Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.